Teladoc Health, Inc. (TDOC)
USD 9.46
(-6.06%)
USD 9.46
(-6.06%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.84 Billion USD | 10.8% |
| 2022 | 1.66 Billion USD | 20.28% |
| 2021 | 1.38 Billion USD | 96.61% |
| 2020 | 703.13 Million USD | 90.63% |
| 2019 | 368.84 Million USD | 27.55% |
| 2018 | 289.17 Million USD | 68.46% |
| 2017 | 171.65 Million USD | 88.25% |
| 2016 | 91.18 Million USD | 61.84% |
| 2015 | 56.34 Million USD | 67.69% |
| 2014 | 33.59 Million USD | 113.73% |
| 2013 | 15.72 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 357.82 Million USD | 1.16% |
| 2024 Q1 | 353.7 Million USD | -24.28% |
| 2024 Q3 | 460.76 Million USD | 28.77% |
| 2023 Q1 | 439.13 Million USD | -2.16% |
| 2023 Q3 | 474.27 Million USD | 2.69% |
| 2023 Q4 | 467.1 Million USD | -1.51% |
| 2023 FY | 1.84 Billion USD | 10.8% |
| 2023 Q2 | 461.86 Million USD | 5.18% |
| 2022 FY | 1.66 Billion USD | 20.28% |
| 2022 Q4 | 448.83 Million USD | 5.41% |
| 2022 Q1 | 378.32 Million USD | -0.24% |
| 2022 Q2 | 409.9 Million USD | 8.35% |
| 2022 Q3 | 425.78 Million USD | 3.87% |
| 2021 FY | 1.38 Billion USD | 96.61% |
| 2021 Q4 | 379.25 Million USD | 7.55% |
| 2021 Q3 | 352.61 Million USD | 2.84% |
| 2021 Q1 | 307.71 Million USD | 18.18% |
| 2021 Q2 | 342.86 Million USD | 11.42% |
| 2020 Q4 | 260.37 Million USD | 41.44% |
| 2020 Q3 | 184.08 Million USD | 22.52% |
| 2020 FY | 703.13 Million USD | 90.63% |
| 2020 Q1 | 108.41 Million USD | 7.2% |
| 2020 Q2 | 150.25 Million USD | 38.59% |
| 2019 Q1 | 83.89 Million USD | 1.43% |
| 2019 Q3 | 95.17 Million USD | 7.36% |
| 2019 Q2 | 88.64 Million USD | 5.66% |
| 2019 Q4 | 101.13 Million USD | 6.27% |
| 2019 FY | 368.84 Million USD | 27.55% |
| 2018 Q3 | 76.79 Million USD | 14.83% |
| 2018 Q1 | 62.78 Million USD | 15.37% |
| 2018 FY | 289.17 Million USD | 68.46% |
| 2018 Q4 | 82.71 Million USD | 7.71% |
| 2018 Q2 | 66.87 Million USD | 6.51% |
| 2017 Q4 | 54.42 Million USD | 4.85% |
| 2017 FY | 171.65 Million USD | 88.25% |
| 2017 Q3 | 51.9 Million USD | 50.18% |
| 2017 Q2 | 34.56 Million USD | 12.37% |
| 2017 Q1 | 30.75 Million USD | 12.36% |
| 2016 Q2 | 19.59 Million USD | 3.44% |
| 2016 Q1 | 18.94 Million USD | 17.23% |
| 2016 Q4 | 27.37 Million USD | 8.33% |
| 2016 FY | 91.18 Million USD | 61.84% |
| 2016 Q3 | 25.26 Million USD | 28.94% |
| 2015 Q1 | 11.2 Million USD | 22.37% |
| 2015 FY | 56.34 Million USD | 67.69% |
| 2015 Q4 | 16.16 Million USD | 4.37% |
| 2015 Q3 | 15.48 Million USD | 14.79% |
| 2015 Q2 | 13.49 Million USD | 20.37% |
| 2014 Q1 | 7.42 Million USD | 0.0% |
| 2014 Q3 | 8.75 Million USD | 5.95% |
| 2014 Q4 | 9.15 Million USD | 4.62% |
| 2014 Q2 | 8.26 Million USD | 11.27% |
| 2014 FY | 33.59 Million USD | 113.73% |
| 2013 FY | 15.72 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Well Corporation | 94.76 Million USD | -1844.263% |
| Doximity, Inc. | 424.75 Million USD | -333.754% |
| Evolent Health, Inc. | 460.47 Million USD | -300.109% |
| MultiPlan Corporation | 306.03 Million USD | -502.01% |
| Phreesia, Inc. | 201.74 Million USD | -813.224% |
| Veeva Systems Inc. | 1.68 Billion USD | -9.251% |